# Gisle Langslet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9112667/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 49 papers | 4,896 citations | 236612 25 h-index | 214527 47 g-index |

| | | | |
|---|---|---|---|
| 50 all docs | 50 docs citations | 50 times ranked | 5015 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1489-1499. | 13.9 | 1,838 |
| 2 | PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 331-340. | 6.3 | 615 |
| 3 | ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal, 2015, 36, ehv370. | 1.0 | 395 |
| 4 | Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, 2014, 63, 1278-1288. | 1.2 | 316 |
| 5 | Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care, 2015, 38, 355-364. | 4.3 | 197 |
| 6 | Long-term Low-Density Lipoprotein Cholesterolâ€“Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. JAMA Cardiology, 2017, 2, 598. | 3.0 | 137 |
| 7 | Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2010, 55, 1121-1126. | 1.2 | 136 |
| 8 | Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. Journal of the American College of Cardiology, 2019, 74, 2132-2146. | 1.2 | 101 |
| 9 | Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet, The, 2015, 385, 2153-2161. | 6.3 | 92 |
| 10 | A phase III randomized trial evaluating alirocumab 300Âmg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis, 2016, 254, 254-262. | 0.4 | 91 |
| 11 | Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies. Cardiovascular Drugs and Therapy, 2014, 28, 281-289. | 1.3 | 86 |
| 12 | Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes and Endocrinology,the, 2014, 2, 455-463. | 5.5 | 84 |
| 13 | Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 359-366. | 1.6 | 84 |
| 14 | Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 195-203.e4. | 0.6 | 56 |
| 15 | Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 390-396.e8. | 0.6 | 51 |
| 16 | Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2015, 13, 477-488. | 0.6 | 50 |
| 17 | Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis, 2014, 233, 561-567. | 0.4 | 48 |
| 18 | Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. Atherosclerosis, 2018, 278, 307-314. | 0.4 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Efficacy and safety of rosuvastatin therapy inÂchildren and adolescents with familial hypercholesterolemia: Results from the CHARONÂstudy. Journal of Clinical Lipidology, 2015, 9, 741-750. | 0.6 | 42 |
| 20 | The heart failure burden of type 2 diabetes mellitusâ€"a review of pathophysiology and interventions. Heart Failure Reviews, 2018, 23, 303-323. | 1.7 | 41 |
| 21 | Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. Journal of Pediatrics, 2015, 167, 338-343.e5. | 0.9 | 40 |
| 22 | LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 279-286. | 0.6 | 39 |
| 23 | Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 1338-1346.e7. | 0.6 | 38 |
| 24 | A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 1153-1162.e3. | 0.6 | 30 |
| 25 | Treatment goal attainment in children with familial hypercholesterolemia: A cohort study ofÂ302 children in Norway. Journal of Clinical Lipidology, 2018, 12, 375-382. | 0.6 | 29 |
| 26 | Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. Journal of Clinical Lipidology, 2018, 12, 1199-1207. | 0.6 | 24 |
| 27 | Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2013, 11, 1061-1066. | 0.6 | 23 |
| 28 | Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood. Journal of Clinical Lipidology, 2015, 9, 778-785. | 0.6 | 19 |
| 29 | Sex differences in cholesterol levels from birth to 19Âyears of age may lead to increased cholesterol burden in females with FH. Journal of Clinical Lipidology, 2018, 12, 748-755.e2. | 0.6 | 19 |
| 30 | Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 | 1.7 | 19 |
| 31 | Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. American Journal of Preventive Cardiology, 2021, 6, 100180. | 1.3 | 16 |
| 32 | Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. European Journal of Human Genetics, 2015, 23, 381-387. | 1.4 | 15 |
| 33 | Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. Diabetes Therapy, 2016, 7, 269-278. | 1.2 | 14 |
| 34 | Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. Journal of Clinical Lipidology, 2019, 13, 138-147. | 0.6 | 14 |
| 35 | Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME<sup>Â®</sup>. Diabetes and Vascular Disease Research, 2020, 17, 147916412097525. | 0.9 | 9 |
| 36 | Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea. European Heart Journal, 2016, 37, 1357-1359. | 1.0 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. Journal of Clinical Lipidology, 2021, 15, 134-141. | 0.6 | 6 |
| 38 | Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia. Atherosclerosis, 2021, 316, 48-52. | 0.4 | 5 |
| 39 | Treatment goals in familial hypercholesterolaemiaâ€”time to consider low-density lipoprotein-cholesterol burden. European Journal of Preventive Cardiology, 2022, 29, 2278-2280. | 0.8 | 5 |
| 40 | Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5253-5262. | 1.8 | 4 |
| 41 | Some children with a familial hypercholesterolemia mutation may exhibit persistent low LDL levels. Journal of Clinical Lipidology, 2018, 12, 1327-1328. | 0.6 | 3 |
| 42 | Familial hypercholesterolemia and young patientsâ€™ thoughts on own condition and treatment. Patient Education and Counseling, 2019, 102, 1005-1012. | 1.0 | 3 |
| 43 | Alirocumab dosing patterns during 40Âmonths of open-label treatment in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 1463-1470. | 0.6 | 2 |
| 44 | Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. Cardiovascular Drugs and Therapy, 2020, 34, 515-523. | 1.3 | 2 |
| 45 | Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis. Journal of Clinical Lipidology, 2021, 15, 375-378. | 0.6 | 2 |
| 46 | Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study. Frontiers in Pharmacology, 2020, 11, 560958. | 1.6 | 2 |
| 47 | Response by Kusters et al to Letter Regarding Article, â€œEffect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)â€• Circulation, 2018, 137, 641-642. | 1.6 | 1 |
| 48 | Authorâ€™s response to: letter to the editor. Heart Failure Reviews, 2018, 23, 819-819. | 1.7 | 0 |
| 49 | Response to the editor. Heart Failure Reviews, 2018, 23, 819. | 1.7 | 0 |